News for iCo Therapeutics Inc - Google Finance

iCo Therapeutics Closes $3.4 Million Financing

Tue, 21 May 2013 12:56:51 GMT

iCo Therapeutics Closes $3.4 Million Financing
Canada NewsWire (press release) - 17 hours ago

VANCOUVER, May 21, 2013 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has closed its previously announced overnight marketed offering (the "Offering").

iCo Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor ...

Wed, 15 May 2013 11:11:22 GMT

iCo Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor ...
Canada NewsWire (press release) - May 15, 2013

VANCOUVER, May 15, 2013 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that management will present a corporate and technology overview along with a milestone event update at the Bloom Burton & Co.

iCo Therapeutics Announces Year End 2012 Financial Results

Thu, 25 Apr 2013 20:06:44 GMT

iCo Therapeutics Announces Year End 2012 Financial Results
Canada NewsWire (press release) - Apr 25, 2013

iCo Therapeutics Announces Year End 2012 Financial Results. VANCOUVER, April 25, 2013 /CNW/ - iCo Therapeutics (TSX-V: ICO), today reported financial results for the year ended December 31, 2012. Amounts, unless specified otherwise, are expressed ...

IIROC Trade Resumption - iCo Therapeutics Inc. - Stockhouse

Fri, 10 May 2013 14:56:35 GMT

IIROC Trade Resumption - iCo Therapeutics Inc. - Stockhouse
Stockhouse - May 10, 2013

IIROC can make a decision to impose a temporary suspension of trading in a security of a publicly listed company, usually in anticipation of a material news announcement by the company.

Isis Pharmaceuticals Inc (ISIS): Today's Most Compelling Stock Buy

Fri, 17 May 2013 17:29:20 GMT

Isis Pharmaceuticals Inc (ISIS): Today's Most Compelling Stock Buy
NASDAQ - May 17, 2013

As of December 31, 2011, the Company owns 20% interests in Santaris Pharma A/S, Achaogen Inc., and Atlantic Pharmaceuticals Limited, which are privately-held, and Antisense Therapeutics Limitet (ATL), and iCo Therapeutics Inc., which are publicly ...

EpiCept Reports First Quarter 2013 Operating and Financial Results - 4 Traders

Mon, 20 May 2013 04:08:27 GMT

EpiCept Reports First Quarter 2013 Operating and Financial Results - 4 Traders
4-traders (press release) - May 20, 2013

Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed exclusive worldwide rights to bertilimumab in 2006 ...

VIVUS, INC. : First Manhattan Files Preliminary Proxy Materials with SEC for ...

Wed, 01 May 2013 19:14:41 GMT

VIVUS, INC. : First Manhattan Files Preliminary Proxy Materials with SEC for ...
4-traders (press release) - May 1, 2013

Prior to Consolidated Graphics, he spent 14 years at ICO, Inc., a manufacturer of specialty resins and provider of polymer processing services, including serving as Senior Vice President, Chief Financial Officer, Treasurer, a director, and for a time ...

First Manhattan Files Preliminary Proxy Materials with SEC for the Election of ...

Thu, 02 May 2013 13:36:52 GMT

First Manhattan Files Preliminary Proxy Materials with SEC for the Election of ...
DailyFinance - May 2, 2013

Pharmaceutical awards honour UBC team

Mon, 06 May 2013 21:29:38 GMT

Pharmaceutical awards honour UBC team
Laboratory Products News - May 6, 2013

He is a University Distinguished Scholar, CIHR/ICO Therapeutics Research Chair in Drug Delivery for Neglected Global Diseases and is a Fellow of the Canadian Academy of Health Sciences.

iCo Therapeutics Inc Announces Overnight Marketed Equity Offering

Thu, 09 May 2013 20:00:00 GMT

iCo Therapeutics Inc Announces Overnight Marketed Equity Offering
Reuters Key Development - May 9, 2013